Clinical Trial

An Open-Label Extension Study of PGN-EDODM1 in People With Myotonic Dystrophy Type 1 (FREEDOM-OLE)

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The purpose of this study is to learn about the long-term safety and tolerability of PGN-EDODM1 in participants with myotonic dystrophy type 1 (DM1) who have completed a prior study with PGN-EDODM1.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2025-10-22; most recent amendment 2026-03-26.
Status change: Not Yet Recruiting → Recruiting 2026-01-08
Trial Details
NCT Number NCT07220603
Lead Sponsor PepGen Inc
Conditions Myotonic Dystrophy 1
Enrollment 48 participants
Start Date 2025-12-23
Primary Completion 2029-01 (estimated)
Study Completion 2029-01 (estimated)
Updated on ClinicalTrials.gov 2026-03-30